Flash Proton Therapy - Potentials and Pitfalls



Jan Schuemann

Associate Professor Head of the Multi-Scale Monte Carlo Modeling Lab Massachusetts General Hospital & Harvard Medical School






MASSACHUSETTS GENERAL HOSPITAL

Background

- Extremely high dose-rate (EDR/Flash) irradiations have been shown to reduce radiation \star damage of normal, healthy tissue in mice, but **NOT in tumors**.
- \star Flash > 40 Gy/s
- ★ Flash proton therapy can use already existing treatment systems
- Flash proton therapy has the potential to fundamentally change radiation therapy

Electron - Flash:







A lot more since then.

OPEN Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome

Bhanu Prasad Venkatesulu^{1,6}, Amrish Sharma^{1,6}, Julia Ramaswamy Sadagopan³, Jessica Symons ^{1,4}, Shiny Ramesh Tailor³, Steven H. Lin^{1,2,4*} & Sunil Krishnan^{1,2,}

Recent reports have shown that very high dose rate radiatio tends to spare the normal tissues while retaining the therap series of experiments to assess if ultra-high dose rate of 350

Radiotherapy and

Radiothera

Contents lists

journal homepage:

Original Article

ELSEVIEI

PHASER: A platform for clinical translat

Peter G. Maxim^{a,***}, Sami G. Tantawi^{b,**}, Billy W. **Original Article** ^a Department of Radiation Oncology, Indiana University School of Medicine; ^b SLA

Institute, Stanford University School of Medicine, United States

ARTICLE INFO

Article history

ABSTRAC



	Contents lists
5-72 EN	Radiothera
ELSEVIER	journal homepage

Jean Bourhis^{a,b,*}, Wendy Jeanneret Sozzi^a, Patrik Gonçalves Jorge^{a,b,c}, Olivier Gaide^d, Claude Bailat^c, Radiotherapy an Fréderic Duclos ^a, David Patin ^a, Mahmut Ozsahin ^a, François Bochud ^c, Jean-François Germond ^c, Raphaël Moeckli^{c,1}, Marie-Catherine Vozenin^{a,b,1}

^a Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; ^b Radiation Oncology Laboratory, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne; ^c Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne; and ^d Department of Dermatology, Lausanne University Hospital and University of Lausanne, Switzerland

Original Article

Dosimetric and preparation procedures for irradiating biological models with pulsed electron beam at ultra-high dose-rate

ABSTRACT

Patrik Gonçalves Jorge^{a,c,d}, Maud Jaccard^a, Kristoffer Petersson^{a,c,d}, Maude Gondré^a, Maria Teresa Durán Laurent Desorgher^a, Jean-François Germond^a, Philippe Liger^b, Marie-Catherine Vozenin^{c,d}, Jean Bourhis^{c,d}, François Bochud^a, Raphaël Moeckli^{a,1}, Claude Bailat^{a,*,1}

^a Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland; ^b PMB-Alcen, Peynier, France; ^c Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; ^d Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland




Beams

Original Article

Elke Beyreuther ^{a,b,*}, Michael Brand ^c, Stefan Hans ^c, Katalin Hideghéty ^d, Leonhard Karsch ^{b,e} Elisabeth Leßmann^a, Michael Schürer^t, Emília Rita Szabó^d, Jörg Pawelke^{b,e}


^a Helmholtz-Zentrum Dresden – Rossendorf, Institute of Radiation Physics; ^b OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf; Center for Molecular and Cellular Bioengeneering (CMCB), DFG-Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Germany; ^dAttosecond Light Pulse Source, ELI-HU Nonprofit Ltd., Szeged, Hungary; ^eHelmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay; and ^fNational Center for Tumor Diseases (NCT), Germany





Check for updates





Treatment of a first patient with FLASH-radiotherapy

journal homepage: www.thegreenjournal.com

Feasibility of proton FLASH effect tested by zebrafish embryo irradiation



neuroinflammation

Danielle A. Simmons^{a,#}, Frederick M. Lartey^{b,c,#}, Emil Schüler^b, Marjan Rafat^{b,d}, Gregory King^b, Anna Kim^b, Ryan Ko^b, Sarah Semaan^a, Selena Gonzalez^a, Melissa Jenkins^b, Pooja Pradhan^b, Zion Shih^b, Jinghui Wang^b, Rie von Eyben^b, Edward E. Graves^{b,e}, Peter G. Maxim^{b,f,*}, Frank M. Longo^{a,*}, Billy W. Loo Jr.^{b,e,*}


^aDepartment of Neurology and Neurological Sciences, ; ^bDepartment of Radiation Oncology, Stanford University School of Medicine; ^cThe Jackson Laboratory, Sacramento ^dDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville; ^e Stanford Cancer Institute, Stanford University School of Medicine; and [†]Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, United States



tal and University of

hole mouse brain





Options of technologies for clinical translation

- ★ Electrons
- ★ MV photons
- ★ Protons
- ★ lons
- ★ Intra-operative (electrons or kV photons)

\star My personal opinions.









Electrons

- ★ 'Original' Flash irradiator
- ★ Highly flexible dose rate
- ★ Single pulse control
- ★ Multiple in vivo experiments
- ★ Already performed clinical 'test'

★ Caveats:

- ★ Low energy / low penetration depth
- ★ Specialized research machine







Bourhis, J., et al. (2019). Radiotherapy and Oncology, 139, 18.

J. Schuemann, LLU, 2020






MV photons

- ★ Linac based approaches
- ★ Used for small animals
- ★ Clinically usable Flash dose rates (up to 120 Gy/s in position 3)
- ★ Flatness good enough for preclinical studies

★ Reversible to standard clinical operation










PHASER

- ★ Originally designed to reduce motion effects and provide cost effective easily transportable RT module
- ★ No moving parts
- ★ Initially Photons
- ★ Later: very high energy electrons (100-200 MeV)
- ★ Achieves Flash-like dose rates







Maxim, P. G., Tantawi, S. G., & Loo, B. W. (2019). Radiotherapy and Oncology, 139, 28–33.








Intra-Op

★ Often not thought of ★ Short distance from accelerator ★ High dose rates often 'readily' available ★ Potentially limited to shorter applicators ★ IORT provides limited applications











Protons and heavy ions


- ★ Several small animal systems designed (protons)
- ★ No heavy ion Flash machine yet

★ Bragg peak vs. Shoot through?

- ★ For small animals both is OK
- ★ Flash is normal tissue effect, Bragg peak in tumor.
- ★ For patients:
 - Is it worth giving up the Bragg peak for the Flash effect?















The case for protons - Distal Layer

- ★ Proton therapy typically dolivers treatments laver by layer
- ★ Starting with the
- ★ Distal layer is alw
- ★ Sometimes in OA
- \star High RBE \rightarrow pote
- ★ Potentially high i




* #







Treatment Room at UMCG



by Drosoula Giantsoudi










The case for protons - Scattering

- ★ 'Instant' distal layer
- \star Usually repainted multiple times (RMW rotation)
- ★ Dose rate in proximal layers likely not Flash
- ★ Dose rate depends on
 - ★ Field size
 - ★ Accelerator current
- ★ Good for small fields

\star Is it worth giving up the dose distribution achievable with scanning?







M. Chuong et al., J Gast. Onc. 2018






The case for protons - Scanning


- ★ High dose rate in single pencils
- ★ Lateral scanning is fast
- ★ Depth scanning not as fast
- ★ What about the penumbra of each pencil?
- ★ No more rescanning (is it needed?)
- ★ May need highly reduced spot map

\star Is it better?




Dose





Dose Rate








Optimal targets / first targets


- ★ Radiosurgery (already high dose and dose rate)
- ★ Sites with current hypofractioantion (e.g. liver, lung, brain) ★ how will it impact of number of fields
- ★ Will Flash lead to hypofractionation for sites without current hypofractionation?
- ★ Sites where NTCP is currently limiting our ability to escalate dose
- ★ Moving targets (requires imaging)
- \star Intra-operative radiation (e.g. pancreas)






Courtesy J. Daartz





2 beam spots (single spot each)







Research questions to be answered in future studies

- \star What is the underlying mechanism(s)?
 - \star Single or multiple involved mechanisms (de-oxygenation, lymphocytes, inflammation, ...)
- \star How robust is the effect?
- \star What are the timing constraints?
 - ★ Intra fraction time limitations
 - ★ Inter fraction time and number limitations
- \star Are there a field size effects?

- \star What happens at the field edges (high dose, high but not Flash dose rate)? \star Hypofractionation-Flash vs. fractionated treatments (the 4 Rs) ★ How does the Flash Effect interact with other treatments/drugs?







Concluding remarks


- \star Many groups are working on answering the outstanding questions
- ★ There is a large potential for Flash
- ★ But also many pitfalls
- ★ Predestined for small tumors?

★ Flash vs. SBRT

- ★ Large tumors:
 - Technical challenges \star
 - Gaps in understanding of the mechanism \star
- ★ Translation into the clinic should not be rushed







★ Potential Benefit of single treatment, even if Flash is only as good as fractionation





Acknowledgements

- MGH Physics group \bigstar
- MGH Radiation Biology group \bigstar
- Steele Lab \star
- **TOPAS** and **TOPAS**-nBio collaborations \star
- RRS and its members \star
- Funding agencies: \star
- NIH/NCI \star
- **Damon Runyon Foundation** \bigstar
- The Brain Tumour Charity \star
- And many more. \star







